<code id='E80645AC06'></code><style id='E80645AC06'></style>
    • <acronym id='E80645AC06'></acronym>
      <center id='E80645AC06'><center id='E80645AC06'><tfoot id='E80645AC06'></tfoot></center><abbr id='E80645AC06'><dir id='E80645AC06'><tfoot id='E80645AC06'></tfoot><noframes id='E80645AC06'>

    • <optgroup id='E80645AC06'><strike id='E80645AC06'><sup id='E80645AC06'></sup></strike><code id='E80645AC06'></code></optgroup>
        1. <b id='E80645AC06'><label id='E80645AC06'><select id='E80645AC06'><dt id='E80645AC06'><span id='E80645AC06'></span></dt></select></label></b><u id='E80645AC06'></u>
          <i id='E80645AC06'><strike id='E80645AC06'><tt id='E80645AC06'><pre id='E80645AC06'></pre></tt></strike></i>

          Home / fashion / focus

          focus


          focus

          author:Wikipedia    Page View:77
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In